What is it about Subiaco based listed biotech minnow Phylogica that has attracted research interest from international billion dollar pharmaceutical giants like Roche , Johnson & Johnson , Astra Zeneca and Pfizer.
The company recently announced its 5th International research partnership deal, this time with the $40b pharmaceutical colossus Genentec, the terms of which have been kept under wraps.
Phylogica have patented their own strain of unique “Peptides” which are fragments of proteins that travel naturally through the body.
The Phylogica Peptide has been uniquely developed to breach the walls of a cell including that of a cancerous cell in order to deliver drugs directly inside the cell.
Currently only very small “molecules” are able to breach cancerous cell walls in order to deliver chemotherapy drugs inside a cell. However they also kill off most other healthy cells along the way and are not able to completely and adequately breach a cell wall.
Phylogica Peptides are capable of carrying or “towing” a new generation of smart drugs, which are much larger in size, directly into the core of a cancerous cell without causing any harmful side-effects.
Whilst Phylogica are concentrating on cancer, their cell breaching technology is designed to be used on almost any disease making it a medical game changer if they can pull it off.